Immunogenicity and Efficacy of a Trivalent HSV-2 gC2, gD2, gE2 Nucleoside-Modified mRNA-LNP Vaccine Against HSV-1 Eye Infection and Neuroinvasion in Mice
Entry updated:
A preclinical, peer-reviewed mouse study from the University of Pennsylvania group (Friedman, Cohen, Awasthi and colleagues) testing their trivalent gC2/gD2/gE2 nucleoside-modified mRNA-LNP vaccine — the same design behind BNT163 — against HSV-1 eye infection and spread to the nervous system. Findings are in an animal model and do not, on their own, establish protection in humans.
This peer-reviewed paper comes from the University of Pennsylvania laboratory (Harvey Friedman, Gary Cohen, Sita Awasthi and colleagues) behind the trivalent gC2/gD2/gE2 mRNA approach that was licensed to BioNTech and became BNT163. It extends the trivalent design’s evidence base to HSV-1 disease of the eye and to neuroinvasion — the virus’s spread into the nervous system — in a mouse model.
The key qualifier is the model: these are preclinical, animal results. Immunogenicity and protection in mice are a necessary early step, not a substitute for human data, and results in animals frequently do not translate directly to people. It matters here because it broadens the preclinical rationale for the trivalent platform beyond genital HSV-2, but the clinical questions are still being tested in the Phase 1 trial of BNT163.